📅 PUBMED DAILY TRIAGE — 2026-07-26

Window: 2026-07-25T00:00:00Z → 2026-07-26T09:00:00Z (CRDT)
Topics scanned: 9 watchlist + 1 sentinel
Candidates reviewed: ~100 PMIDs across all topics
Articles retained: 34 (7 HIGH | 27 STANDARD | 0 LOW in output)
Unsolicited finds: 3
Run status: ⚠️ PARTIAL_SUCCESS — T4/T5/T6/T7 esummary batches truncated; 42 candidate PMIDs not confirmed (see notes)

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy / ctDNA)

PMID-42499691 · Comprehensive Liquid Biopsy Testing in Metastatic HR+/HER2- Breast Cancer: First Results from Routine Clinical Practice · 9/10 · 🔴 EARLY_CANCER_DETECTION

Real-world validation (N=162) showing ctDNA detects ESR1 mutations in 28.4% of mBC patients with direct treatment switch to elacestrant in 43.5% — first major routine-practice implementation dataset.

AI/ML in Clinical Diagnostics & Precision Oncology

PMID-42502133 · Prediction of single cell expression from low-plex immunofluorescence images for guiding precision oncology · 9/10 · 🟠 NOVEL_TREATMENT

Image2Count GNN model predicts 960-plex single-cell expression from just 4-marker immunofluorescence images, validated in 3 cancer types; enables affordable clinical tumor immune microenvironment profiling.

Cardiovascular-Metabolic

PMID-42501951 · Rationale, Design, and Experiences from the Vanguard Phase of the BRAVE Trial · 9/10 · 🟠 NOVEL_TREATMENT

First-ever large international RCT (17 centers, 4 countries) randomizing bariatric surgery vs medical management for cardiovascular event reduction in high-risk obese patients; 200-patient vanguard confirms feasibility.

Rare Diseases / Transplant Medicine

PMID-42501920 · Pretransplant Gut Microbiome Signatures Predict Early Acute Rejection After Kidney Transplantation · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE

Pretransplant stool metagenomics (AUC 0.765 in temporal validation) outperforms clinical-only models for predicting early acute kidney rejection; microbiome-based pretransplant risk stratification ready for prospective evaluation.

Novel Therapeutics (Immunotherapy)

PMID-42501476 · Cadonilimab for recurrent small cell neuroendocrine carcinoma of the cervix: a phase 2 study · 8/10 · 🟠 NOVEL_TREATMENT

Bispecific anti-PD-1/CTLA-4 cadonilimab in an ultra-rare aggressive gynecologic cancer (N=9): 0% ORR, safe; first prospective data for dual checkpoint blockade in SCNCC — informs future combination design.

Rare Diseases / Ophthalmology

PMID-42501956 · Retinal Pigment Epithelium and Microglia Transplantation in Age-related Macular Degeneration · 7/10 · 🟠 NOVEL_TREATMENT (flag-elevated)

Review of emerging RPE + microglia co-transplantation strategies for AMD with early clinical trial data; addresses major unmet need in a blinding progressive disease.

Hematologic Malignancies (Precision Medicine)

PMID-42500906 · Rapid Molecular Diagnostics Enables Individualized Frontline Treatment of CBFA2T3::GLIS2-Rearranged AML · 7/10 · 🟠 NOVEL_TREATMENT (flag-elevated, 2-patient series exception)

Nanopore WGS enabled same-session identification of CBFA2T3::GLIS2 rearrangement (27% 5-yr EFS) → upfront azacitidine + venetoclax + gemtuzumab; proof-of-concept for rapid-WGS-guided personalized frontline therapy in rare pediatric AML.

🟢⚪ STANDARD (5-7) — Top by Topic

Hematologic Malignancies

• 42501071 · Standardized FDG-PET in R/R DLBCL during CAR T-cell therapy (DESCAR-T, N=212) · 7/10 · TMTV >30cm³ + Deauville score thresholds define CAR-T response standards (🟢 NEAR_TERM_IMPLEMENTABLE)
• 42501554 · ML-guided discovery of withangulatin A as TYK2 inducer in non-APL leukemia · 7/10 · Natural product + ML preclinical target validation in primary human AML cells (⚪ PROMISING_PRELIMINARY)
• 42502080 · Romiplostim RCT for CIT in pediatric cancers (N=93) · 6/10 · No platelet recovery acceleration but significant bleeding reduction — pediatric-specific data gap filled
• 42501316 · HLA-haploidentical anti-CD7 CAR T in transplant-naïve T-ALL · 3/10 · Letter; novel approach bypassing HSCT requirement for T-ALL (sparse topic exception; score capped at 3 per title-only rule)
• 42501515 · ASO therapy in hematological malignancies: review · 5/10 · Early-phase trial synthesis for MDS/AML/ALL/CLL

Novel Therapeutics

• 42501801 · High-payload AODC (antibody-oligonucleotide-drug conjugates) for chemo-immunotherapy · 7/10 · Novel ADC modality with gemcitabine prodrug + immunogenic cell death + PD-1 combo efficacy in preclinical models (⚪ PROMISING_PRELIMINARY)
• 42502043 · STING-mediated cancer immunotherapy: emerging modalities (Trends Pharmacol Sci) · 5/10 · Review identifying pulsatile/biomimetic STING activation strategies to overcome immune exhaustion barrier

AI/ML in Diagnostics

• 42501941 · Sex-specific ML improves COPD prediction (Chest, N=3123, external validation) · 7/10 · Female-only model AUC 0.86 vs 0.78 combined; argues for sex-disaggregated AI diagnostics (🟢 NEAR_TERM_IMPLEMENTABLE)
• 42501874 · AI workflow for incidental pulmonary nodule follow-up in ED · 5/10 · Notification 75%→88.4%, follow-up 53.5%→67.9%; near-term deployable ED AI workflow

Precision Oncology

• 42501604 · MULTIPREVENT: Integrated LDCT + genomics + AI screening for smoking-related multimorbidity (N=3000 protocol) · 5/10 · Protocol paper; large prospective AI-integrated multimorbidity prevention platform

Cardiovascular-Metabolic

• 42502078 · Trdn-as lncRNA + m6A METTL3 → triadin isoform switching → dilated cardiomyopathy (Nat Commun) · 7/10 · Novel cardiac lncRNA mechanism validated in KO mice + human iPSC-CMs + patient tissue (⚪ PROMISING_PRELIMINARY)
• 42502138 · T2D precision subtypes (SIDD/SIRD/MOD/MARD): methodological challenges (Diabetologia) · 5/10 · Critical review identifying three fundamental flaws in T2D subtyping approach
• 42502148 · Early warning + behavioural intervention for CVD risk in PLHIV: multicenter non-RCT · 6/10 · Sentinel find; HIV-CVD intersection prevention trial (unsolicited)

Aging, Longevity & Population Health

• 42501130 · Transcriptomic landscape of human cardiac aging: GTEx RNA-seq, 393 genes, ML prediction model · 7/10 · Cardioselective aging gene signature + elastic net model; QWK 0.797 internal, R²=0.20-0.38 external (⚪ PROMISING_PRELIMINARY)
• 42499153 · Neuropathology in diverse oldest-old cohort: LifeAfter90 study · 7/10 · Diverse autopsy cohort examining AD neuropathology in 90+; high-impact journal (Alzheimer's & Dementia)
• 42499147 · Reserve and resilience challenges in aging and AD: narrative review (Alzheimer's & Dementia) · 5/10 · Methodological critique of brain reserve operationalization; multi-institution authorship
• 42500670 · Immunosenescence modulates radiation-induced anti-tumor immunity: implications for personalized immuno-oncology · 5/10 · Bridges aging/immunosenescence with radiation + checkpoint immunotherapy
• 42500653 · Decoding the tumor-aging axis: from bench to clinical (Front Immunol, pmcrefcount=215) · 5/10 · High-citation review on senescence/inflammaging/immunosenescence in cancer

Rare Diseases

• 42499730 · Endoscopic findings in Shwachman-Diamond syndrome: North American SDS Registry (N=45, 102 procedures) · 7/10 · First systematic GI endoscopy characterization in SDS; post-HSCT GVHD patterns identified (🟡 UNDERSERVED_POPULATION)
• 42500915 · Hereditary angioedema: on-demand treatment and long-term prophylaxis — global access review · 5/10 · Global treatment access perspective for HAE; unmet need emphasis
• 42500675 · Persistent IBD disease burden despite advanced therapies: real-world survey, Greece · 5/10 · Real-world evidence of unmet need in IBD treatment

💡 UNSOLICITED FINDS (Sentinel Scan)

📊 TODAY'S BREAKDOWN

By pipeline priority:

• HIGH: 7 articles (score ≥8 or EARLY_CANCER_DETECTION/NOVEL_TREATMENT flag)
• STANDARD: 27 articles (score 4–7)
• LOW: 0 in output (articles scoring ≤3 counted only in per_topic_stats)

By evidence maturity:

• Potentially Practice-Changing: 1 (BRAVE trial design)
• Validated: 6 (ctDNA clinical practice, Image2Count, gut microbiome-rejection, COPD sex-ML, FDG-PET DLBCL, AI lung nodule ED)
• Exploratory: 27

By study design:

• RCT / trial design: 3 (42502080 romiplostim, 42501951 BRAVE, 42501476 cadonilimab)
• Cohort / registry / prospective: 6 (42499691, 42501920, 42501941, 42501071, 42501130, 42499153)
• Preclinical (in vivo + human cells): 4 (42501554, 42501801, 42500570, 42502078)
• Review: 17
• Protocol: 1 (42501604)
• Case series / Letter: 3 (42500906, 42501316, 42501867)

By research category:

• Treatment Innovation: 10
• Diagnostics: 7
• Early Detection: 3
• Genomics/Precision Medicine: 4
• Drug Development: 5
• Prevention: 3
• Public Health: 2

By watchlist topic (reviewed / retained / highest score):

*42502133 shared across T4/T5

Topics with zero 8+ articles this run (watchlist-specific):

• T1: Hematologic malignancies (best score 7; NOVEL_TREATMENT flag applied to 2 articles → both elevated to HIGH)
• T2: CBC/ML hematology (zero results)
• T8: Aging/longevity (best score 7, no flag elevation)

🔧 RUN NOTES

1. T2 zero results: Both primary and fallback queries returned 0 results for the 2026-07-25 → 2026-07-26 CRDT window. No CBC/ML hematology articles entered PubMed in this 33-hour window.

2. Partial coverage (PARTIAL_SUCCESS): T4, T5, T6, and T7 esummary batch responses exceeded the tool display truncation threshold (~20KB per response). Abstract retrieval compensated for top candidates in each topic. Unreviewed PMIDs documented in search_logs: T4 (11 missing), T5 (11 missing), T6 (10 missing), T7 (10 missing).

3. Conservative scoring applied:

• 42500906 (Nanopore WGS, 2-patient series): sparse-topic + rare-disease-signal exception applied; NOVEL_TREATMENT flag elevates to HIGH
• 42501316 (HLA-haplo CAR-T T-ALL, Letter): included under sparse-topic exception; classification_confidence=low
• 42501867 (CAR-T vs Glofit-GemOx, Letter): included under sparse-topic exception; title-only

4. False positives in T1: 3 articles (42501697 cardiac MLL4, 42502071 Chinese ALK-TKI consensus, 42502001 Spanish myelofibrosis case) appeared in hematology search but were off-topic; scored LOW and excluded from output. Indicates search query picks up broad "leukemia/lymphoma" keyword matches in unrelated contexts.

5. Sentinel coverage: 261 raw sentinel hits; top 10 reviewed; 42502080 and 42502099 already reviewed under T1/T9 respectively; 3 new unsolicited finds retained.

Generated by Friday (OpenClaw) · Run ID: 2026-07-26-attempt2-20260726T092858Z · Attempt 2 of 3 · Repairs: pmid type (int→str), title-only score caps (42501316: 6→3, 42501867: 5→3), Aging topic PMID 42500861 accounting